Collegium Pharmaceutical, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Collegium Pharmaceutical, Inc. (COLL) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$101.78 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-06
- Collegium Pharmaceutical, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was $37.40M, a 82.59% increase year-over-year.
- Collegium Pharmaceutical, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was $20.48M.
- Collegium Pharmaceutical, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$10.34M, a 110.79% decline year-over-year.
- Collegium Pharmaceutical, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was $95.79M.
- Collegium Pharmaceutical, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $155.55M.
- Collegium Pharmaceutical, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$143.38M, a 324.88% decline from fiscal 2023.
- Collegium Pharmaceutical, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $63.76M.
- Collegium Pharmaceutical, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$12.74M, a 203.48% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$101.78M 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $37.40M 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $155.55M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $74.39M 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $41.64M 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | $20.48M 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | -$143.38M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | -$174.99M 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | -$66.05M 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | -$10.34M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $63.76M 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $83.34M 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | $108.56M 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | $95.79M 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | -$12.74M 10-K · filed 2025-02-27 | |||
| 2022-09-30 | -$52.30M 10-Q · filed 2023-11-07 | |||
| 2022-06-30 | -$63.70M 10-Q · filed 2023-08-03 | |||
| 2022-03-31 | -$79.73M 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | $12.31M 10-K · filed 2024-02-22 | |||
| 2021-09-30 | $19.13M 10-Q · filed 2022-11-03 | |||
| 2021-06-30 | $28.66M 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | $8.67M 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $6.64M 10-K · filed 2023-02-23 | |||
| 2020-09-30 | -$2.05M 10-Q · filed 2021-11-04 | |||
| 2020-06-30 | -$21.79M 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | -$51.20M 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | $23.39M 10-K · filed 2022-02-24 | |||
| 2019-09-30 | $7.21M 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | $2.08M 10-Q · filed 2020-08-05 | |||
| 2019-03-31 | -$11.72M 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | $27.84M 10-K · filed 2021-02-25 | |||
| 2018-09-30 | $21.00M 10-Q · filed 2019-11-06 | |||
| 2018-06-30 | $14.95M 10-Q · filed 2019-08-07 | |||
| 2018-03-31 | $10.16M 10-Q · filed 2019-05-08 | |||
| 2017-12-31 | -$34.53M 10-K · filed 2020-02-27 | |||
| 2017-09-30 | -$45.61M 10-Q · filed 2018-11-08 | |||
| 2017-06-30 | -$42.02M 10-Q · filed 2018-08-08 | |||
| 2017-03-31 | -$23.67M 10-Q · filed 2018-05-09 | |||
| 2016-12-31 | $57.53M 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |